Mama's Creations Inc（MAMA）のニュースとイベントMAMAMama's Creations Inc

Mama's Creations Q2 Revenue Reaches $54.58M

Reports Q2 revenue $54.58M, consensus $52.85M. Adam Michaels, chairman and CEO of Mama's Creations, said: "The second quarter was another step-change quarter for Mama's. Thanks to the creativity of our sales team, the resilience of our operations team and the increased capacity from the September 2025 Bay Shore acquisition, revenue grew 55% to $54.6 million and adjusted EBITDA grew 69% to $5.5 million. Though the real story of the quarter is not the impressive growth rate, but the shape of it. Every bottom-line metric grew faster than revenue year-over-year, with net income more than doubling and operating expenses shrinking as a percent of revenue. Gross margin turned back up sequentially as the items we launched in Q1 moved toward steady-state production. That is exactly the sequence we told you to expect: invest into the launch, then harvest the leverage."

William Blair and DA Davidson Jointly Manage Offering with Deal Range of $17.50-$18.50

The deal range was $17.50-$18.50. William Blair and DA Davidson acted as joint book running managers for the offering.

Stock Futures Slightly Lower as Investors Await Middle East News

Stock futures were fractionally lower following Monday's regular session gains as investors await news out of the Middle East. President Trump said the U.S. and Iran will meet to negotiate after days of strikes as the market shifts focus from geopolitics back toward macro data. Investors are watching labor market releases, including the JOLTS report and Thursday's payroll report, for clues on the Federal Reserve path. Markets continue to weigh a resilient economy against concerns that sticky inflation could keep the Fed more restrictive than expected.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -AeroVironmentup 20.4%ALSO HIGHER -BTC Digitalup 160.7% after announcing a $28M private placementGain Therapeuticsup 20.2% after receiving FDA clearance of its GT-02287 IND applicationBiomXup 13.7% after filing to sell 7.16M shares of common stock for holdersTradewebup 2.1% after Goldman Sachs upgraded the stock to Buy from NeutralDOWN AFTER EARNINGS -Concentrixdown 22.2%ALSO LOWER -GMEX Roboticsdown 26.4% after announcing a 1-for-9 share consolidationNuvectisdown 19% after announcing a common stock offeringMama's Creationsdown 12.8% after announcing a common stock offering